Journal Home
Search for

Volume 60, Issue 1, Pages 154-157 (January 2009)


View previous. 37 of 52 View next.

Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin

Jayati Acharya, MRCPaCorresponding Author Informationemail address, Calum Lyon, MA, FRCPb, David M. Bottomley, MRCP, FRCRa

Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.

a Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom

b Department of Dermatology, York District Hospital, York, United Kingdom

Corresponding Author InformationCorrespondence to: Jayati Acharya, MRCP, Department of Clinical Oncology, St James's Institute of Oncology, Beckett Street, Leeds, West Yorkshire, United Kingdom LS9 7TF.

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from authors.

PII: S0190-9622(08)01015-3

doi:10.1016/j.jaad.2008.07.057


View previous. 37 of 52 View next.